Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection.

Next Previous
Trial Profile

Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abacavir (Primary) ; Atazanavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Lamivudine (Primary) ; Lamivudine/zidovudine (Primary) ; Lamivudine/zidovudine/abacavir (Primary) ; Nevirapine (Primary) ; Stavudine (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Zidovudine (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use

Most Recent Events

  • 23 Aug 2020 Results (n=757) of a retrospective, observational cohort of individuals receiving primary care at the vanderbilt comprehensive care clinic and a retrospective analysis of a clinical trials (A5095, A5142 and A5202 and did not receive INSTIs) cohort from efavirenz containing arms of ACTG protocols has been published in the Clinical Infectious Diseases.
  • 03 Apr 2012 Additional trial location (Puerto Rico) added as reported by ClinicalTrials.gov.
  • 03 Apr 2012 Planned patient number is 1125 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top